Genome-wide linkage scan for loci influencing plasma triglyceride levels by Peralta, JM et al.
PROCEEDINGS Open Access
Genome-wide linkage scan for loci
influencing plasma triglyceride levels
Juan M. Peralta1,2*, Nicholas B. Blackburn1,2, Arthur Porto1, John Blangero1,2 and Jac Charlesworth2
From Genetic Analysis Workshop 20
San Diego, CA, USA. 4 - 8 March 2017
Abstract
We conducted a genome-wide linkage scan to detect loci that influence the levels of fasting triglycerides in
plasma. Fasting triglyceride levels were available at 4 time points (visits), 2 pre- and 2 post-fenofibrate intervention.
Multipoint identity-by-descent (MIBD) matrices were derived from genotypes using IBDLD. Variance-component
linkage analyses were then conducted using SOLAR (Sequential Oligogenic Linkage Analysis Routines). We found
evidence of linkage (logarithm of odds [LOD] ≥3) at 5 chromosomal regions with triglyceride levels in plasma. The
highest LOD scores were observed for linkage to the estimated genetic value (additive genetic component) of the
log-normalized triglyceride levels in plasma. Our results suggest that a chromosome 10 locus at 37 cM (LODpre = 3.
01, LODpost = 3.72) influences fasting triglyceride levels in plasma regardless of the fenofibrate intervention, and that
loci in chromosomes 1 at 170 cM and 4 at 24 cM ceases to affect the triglyceride levels when fenofibrate is present,
while the regions in chromosomes 6 at 136 to 162 cM and 11 at 39 to 40 cM appear to influence triglyceride levels
in response to fenofibrate.
Background
Triglyceride levels in plasma are highly heritable traits that
have been consistently associated with obesity, cardiovascu-
lar disease, coronary heart disease, Type 2 diabetes, and
metabolic disease. The genetics of triglycerides has been
the subject of extensive research, including both
genome-wide association and genome-wide linkage studies
in a variety of cohorts.
As a result, several loci have been either associated or
linked with changes in triglyceride levels. Li et al. [1]
found linkage between serum triglyceride levels and
chromosome 7 at 174 cM (7:174 cM, logarithm of odds
[LOD] = 3.52) and suggestive linkage to 20:101 cM
(LOD = 2.34), 13:111 cM (LOD = 2.00), and 9:104 cM
(LOD = 1.90) in a sample of 1514 subjects from 320
obese white nuclear families. In a study of atherogenic
dyslipidemia, Yu et al. [2] reported linkage of triglyceride
levels to 11:99 cM (LOD = 3.34) and 17:57 cM (LOD =
3.44) in a Turkish family cohort, and to 8:54 cM (LOD
= 3.08) in an extended mixed family cohort with Euro-
pean, Finnish, and Turkish/Mediterranean ancestry. A
study of Australian dizygotic twins by Middelberg et al.
[3] found linkage between triglyceride levels and
7:65 cM (LOD = 2.94), 4:62 cM (LOD = 2.26), and
X:81 cM (LOD = 2.01), whereas a study of Mexican
American families from Coletta et al. [4] found linkage
of triglyceride levels to 12:24 cM (LOD = 3.8).
Besides design and methodological differences, those
linkage studies share the characteristic of being observa-
tional studies. The Genetics of Lipid Lowering Drugs
and Diet Network (GOLDN) study [5] conducted an
intervention in a cohort of families of European ancestry
with fenofibrate, a drug known to decrease triglyceride
levels in plasma. GOLDN data were collected at 4 time
points (2 before the fenofibrate intervention and 2 after
it) providing an opportunity to investigate the genetic ef-
fects associated with the response to fenofibrate admin-
istration. Hidalgo et al. [6] found, using GOLDN data, a
strong linkage signal for changes in low-density lipopro-
tein cholesterol (LDL-C) near 7:108 cM (LOD = 5.17)
and for changes in high-density lipoprotein cholesterol
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(HDL-C) near 10:37 cM (LOD = 4.75), but reported no
evidence of linkage to either total cholesterol or trigly-
ceride levels.
In this study, we conduct genome-wide linkage scans to
map loci that influence fasting triglyceride levels in plasma
before and after fenofibrate was administered to GOLDN
participants. To do so, we follow a different approach than
the one used by Hidalgo et al. [6]. We used IBDLD [7] to
estimate multipoint identity by descent and empirical kin-
ship information from genome-wide single-nucleotide poly-
morphism (SNP) association data, followed by linkage
analysis using the variance-component framework built
into SOLAR (Sequential Oligogenic Linkage Analysis Rou-
tines) [8].
Methods
Data set
We used real data from the GOLDN study that was
made available to participants of the GAW20. Specific-
ally, SNP dosages from 822 individuals genotyped at
718,407 loci, phenotypes from 1106 individuals, and ge-
nealogies for 4151 individuals in 188 families. Quality
control of the genotype and genealogical information
was conducted using PREST-plus [9], to assess the
agreement of genotype-derived pairwise relatedness in-
ferences with the corresponding genealogy.
Trait and covariates
Fasting triglyceride (TG) levels in plasma (mg/dL) from
peripheral blood, drawn at visits 1 and 2 (pre-) and at visits
3 and 4 (post-fenofibrate intervention), were used to derive
phenotypes consisting of the averaged and log-normalized
pre (log_tg_pre) and post (log_tg_post) fenofibrate TG
levels. In addition, we used the additive genetic component
of the phenotypic variance (estimated genetic value [EGV])
of log-normalized pre (egv_log_tg_pre) and post (EGV_-
log_tg_post) TG levels, as described by Porto et al. [10].
Age, sex, and their interactions, together with smoking sta-
tus and recruitment center, were included as covariates in
all of our linkage models. To account for the possibility of
local substructure or stratification we also included the first
4 principal components, estimated from scored genotypes
in founders and projected to all individuals, as covariates
into our linkage models.
Simulated phenotypes
One thousand heritable traits (SIMQTs) were simulated
using SOLAR (version 8.1.1) [8] with zero mean, unit
variance, and a 35% heritability, but not linked to any
real loci.
Physical and genetic maps
Physical coordinates and annotations for genes and
marker loci were set to be relative to release 19 of the
human genome (hg19) from UCSC. Genetic coordinates
were interpolated, accounting for the local base pair/cM
rate, from a sex-average combined physical and genetic
map [11].
Multipoint identity-by-descent and empirical kinship
estimation
Multipoint estimates of identity-by-descent (MIBD) for
each SNP locus and chromosome-wide empirical kinship
estimates were obtained using IBDLD (version 3.33) [7]
using the genotypes at marker loci remaining after a
stringent linkage disequilibrium (LD)-based pruning of
r2 ≥ 0.9 followed by a filter of minor allele count (MAC)
> 5 using PLINK (version 1.90p) [12]. A genome-wide
empirical kinship matrix was then constructed as the
whitened transform of the weighted average of the auto-
somal chromosome-wide empirical kinship matrices,
using hg19 chromosome lengths (in base pairs) as
weights. MIBD matrices to be used for the linkage scan
were obtained from IBDLD [7] estimates at the marker
loci situated closest to the cM integer units in the gen-
etic map of each chromosome, using all available SNPs
within a 10-cM window around it.
Variance component linkage analysis
The pedigree-based multipoint variance component ap-
proach built into SOLAR [8] was used to evaluate the
linkage between loci in a genetic map at the cM resolution
and the log-normalized pre- and post-fenofibrate TG
levels, as well as their respective estimated genetic values.
Results
Two individuals were excluded from downstream ana-
lyses based on genealogy mismatches (see [13]). One in-
dividual, 8078 (family 333), a known monozygotic twin
of 2921, was also excluded to guard against the artificial
inflation of heritability estimates. Of the initial 718,407
SNPs, 313,728 did not pass our LD filter and 29,047 did
not pass our MAC filter. The remaining 375,632 SNPs
were used in the estimation of MIBD at 3561 loci in our
genetic map.
Heritability estimates for the TG level in plasma before
and after the fenofibrate intervention, and across
SIMQTs ranged between 33 and 48% (Table 1). Black-
burn et al. [13] found little differences (< 5%) in the her-
itability estimates when using an IBDLD-derived
empirical kinship instead of pedigree-derived kinship co-
efficients (which yielded lower heritability estimates). To
be conservative, we used the pedigree-based kinship esti-
mates in our linkage models.
Linkage was detected for log_tg_post in chromosome
10 at 30 cM, with a peak LOD score of 3.35, within a
12-cM region of LOD ≥2 support (Fig. 1; Table 2). In
addition, 2 suggestive linkage signals (LOD ≥2) were
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observed at 6:162 cM and 11:40 cM (Table 2). The link-
age analysis of egv_log_tg_post yielded stronger LOD
score peaks of 4.36 at 10:30 cM, 3.24 at 6:162 cM, and
3.34 at 11:40 cM (Fig. 2; Table 3). Only signals suggestive
of linkage with log_tg_pre were observed (Table 2). One
of these mapped to the locus at 10:32 cM, close to the
region linked to log_tg_post. Significant evidence of
linkage was observed for log_tg_pre at 1:170 cM,
4:24 cM, and 5:122 cM (Fig. 1: Table 2). The analysis of
egv_log_tg_pre improved the magnitude of the LOD
score peaks observed for log_tg_pre, at 1:170 cM and
4:24 cM, beyond the LOD ≥3 threshold for linkage
(Fig. 2; Table 3). Our results also included a number of
suggestive egv_log_tg_pre and egv_log_tg_post loci (data
not shown).
To determine whether our linkage analyses were
biased by the capture of short-range identity-by-descent
(IBD) instead of the expected long-range MIBD esti-
mates, we shifted the point of MIBD estimation by half a
centimorgan in the genetic map. Then we estimated new
MIBD matrices and repeated the linkage analyses of the
log_tg_pre and log_tg_post traits. The resulting linkage
scans contained the same features as those appearing in
Fig. 1, with moderate variation in the magnitude of the
LOD score peaks (data not shown). The most relevant
difference was that with the half centimorgan shift the
Table 1 Heritability estimates
Trait Heritability Standard error Significance
log_tg_pre 0.48 0.07 2.1 × 10− 14
log_trr_post 0.41 0.08 7.2 × 10−9
egv_log_tg_pre 1.00 – –
egv_log_trr_post 1.00 – –
SIMQTa 0.33 0.06 3.4 × 10−4
The heritability of estimated genetic values (egv_log_tg_pre and
egv_log_tgr_post) is, by definition, equal to 1. The sample size of log_tg_pre
(n = 817) was 5% higher than for log_tg_post (n = 774)
aaverage from 1000 simulations
Fig. 1 Genome-wide linkage scan plot of triglyceride levels in plasma. Linkage was defined as LOD ≥3 (horizontal red line); suggestive linkage
was defined as 2 ≤ LOD < 3 (horizontal gray line); SIMQT is the average LOD score across 1000 simulations
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Table 2 Loci linked or exhibiting suggestive linkage to fasting
triglyceride levels in plasma
Trait Chromosome cM LOD h2r h2q1
log_tg_pre 1 170 2.43 0.20 0.40
4 24 2.67 0.12 0.44
4 33 2.04 0.15 0.41
5 122 2.40 0.15 0.42
10 32 2.03 0.18 0.41
14 115 2.06 0.15 0.42
log_tg_post 6 162 2.07 0.09 0.42
10 29 2.36 0.11 0.43
10 30 3.35 0.05 0.51
10 31 2.27 0.10 0.43
10 32 2.69 0.08 0.48
10 33 2.05 0.12 0.43
10 34 2.03 0.13 0.40
10 35 2.01 0.13 0.39
10 36 2.30 0.11 0.43
10 37 2.26 0.10 0.45
10 38 2.00 0.12 0.41
10 41 2.02 0.11 0.43
11 40 2.19 0.07 0.48
Linkage was defined as LOD ≥3 (in bold); suggestive linkage was defined as
2 ≤ LOD < 3. h2r, Residual trait heritability; h2q1, heritability of the quantitative
trait locus
Fig. 2 Linkage scans from chromosome 10 under 3 different models. Expanded view of the linkage scan of chromosome 10 for (a) triglyceride
levels pre- and post-fenofibrate treatment (log_tg_pre and log_tg_post); b their respective estimated genetic values; and c the post-fenofibrate
TG levels after removal of its additive genetic component, as estimated by its estimated genetic value
Table 3 Loci linked to the estimated genetic values of
triglyceride levels in plasma
Trait Chromosome cM LOD h2r h2q1
egv_log_tg_pre 1 170 3.05 0.63 0.37
4 24 3.08 0.57 0.43
10 37 3.01 0.54 0.46
egv_log_tg_post 6 136 3.02 0.57 0.43
6 157 3.21 0.57 0.43
6 162 3.24 0.60 0.40
10 29 3.15 0.60 0.40
10 30 4.36 0.53 0.47
10 32 3.76 0.52 0.48
10 35 3.66 0.53 0.47
10 36 3.60 0.52 0.48
10 37 3.72 0.50 0.50
10 38 3.43 0.54 0.46
10 44 3.17 0.65 0.35
11 39 3.29 0.54 0.46
11 40 3.34 0.49 0.51
Linkage was defined as LOD ≥3. h2r, Residual trait heritability; h2q1, heritability
of the quantitative trait locus
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suggestive peaks for log_tg_pre at 10:30 cM and at
5:122 cM reached the LOD = 3 threshold.
All evidence of linkage disappeared with the removal
of the genetic signal from log_tg_post, accomplished by
the introduction of egv_log_tg_post as covariate into its
linkage model (see Fig. 2).
Across a thousand SIMQT linkage scans we observed
1 scan with LOD scores ≥3.35, 3 scans with LOD scores
≥3, and 33 scans with LOD scores ≥2. The maximum
LOD score observed in the averaged linkage scan from
all SIMQTs was 0.119 (mean = 0.106, SD = 0.004).
Discussion
Hidalgo et al. [6] reported no linkage in their analysis of
TG levels, using a different approach than the one we
followed here. They relied primarily on MERLIN to both
estimate IBD matrices and conduct linkage analyses. This
methodological choice has 2 limitations not present in our
study. First, the use of MERLIN requires large and inform-
ative pedigrees to be reduced in complexity, resulting in a
loss of both information and power. Second, and possibly
more important, it limited the number of loci that Hidalgo
et al. were able to use for IBD inference. Only 10 sets of
approximately 3000 SNPs each were used to perform
“linkage analyses in independent overlapping intervals of
the genome” [6] from 729,490 SNPs that were available to
them for analysis. By using IBDLD [7] we were able to le-
verage the information contained in more than 375,632
SNPs to derive our MIBD estimates at the 3561 loci that
were used in our linkage analyses. IBD was estimated
using all available marker data within 10-cM windows
centered around the locus selected for any given MIBD
matrix, an approach that we believe yielded more robust
and informative IBD estimates. When we shifted our se-
lection of markers by half a centimorgan, our linkage in-
ferences did not change.
We found linkage between the fasting TG levels in
plasma after the intervention with fenofibrate (log_tg_-
post) and a locus that maps to chromosome 10 at 30 cM
(LOD = 3.35; see Table 2). We also discovered evidence
suggestive of linkage at 18 other loci (see Table 2). To
assess the relevance of these loci in the response to the
fenofibrate challenge, while increasing our power to de-
tect linkage (see Porto et al. [10]), we decided to focus
on the purely additive genetic component of the TG
levels, as estimated by their estimated genetic values. By
introducing the estimated genetic values as covariates
into our linkage models we effectively removed the addi-
tive genetic component from the phenotype. The results
we obtained using these models were devoid of any sign
of linkage (see Fig. 2); an indication that the features
from Fig. 1 were not a random artifact and were driven
by the heritable component of the analyzed trait. This
encouraged us to search the genome directly for linkage
with the TG level estimated genetic values. As a result
for most of the loci the LOD scores reached the linkage
threshold, as shown in Table 3. Based on the linkage
analysis of the estimated genetic values it appears that
loci at 1:170 cM and 4:24 cM cease to have an influence
on the TG levels in the presence of fenofibrate, whereas
the regions at 6:136 cM to 6:162 cM and 11:39 cM to
11:40 cM appear to influence TG levels in response to
fenofibrate. The region at 10:29 cM to 10:44 cM appears
to affect TG levels regardless of the fenofibrate interven-
tion. However, it would be premature to interpret these
results as evidence of a possibly differentiated subject re-
sponse to the fenofibrate treatment. A rigorous explor-
ation of the response to the drug treatment, while an
interesting research avenue, was beyond the scope of
this study.
There are precedents in the literature for some of our
findings. The analysis from Liu et al. [14] found suggest-
ive linkage signals for combined TG/HDL levels within
the 6:129 cM to 6:155 cM region in the Framingham
Heart Study cohort. Middelberg et al. [3] reported link-
age to 4:62 cM, in the vicinity of the feature that con-
tains our 4:24 cM linkage (see Fig. 1). While the linkage
to 11:99 cM described by Yu et al. [2] is far from our
11:39 cM to 11:40 cM signal, we did find suggestive link-
age to the estimated genetic value of post-fenofibrate
treatment at 11:114 cM (LOD = 2.94). Finally, Hidalgo et
al. [6] described linkage to 10:30 cM to 10:50 cM for
changes in HDL-C.
Conclusions
We demonstrated that conducting linkage scans with
MIBD matrices estimated from dense SNP loci is feas-
ible. Focusing our analyses on the additive genetic com-
ponent of the trait allowed us to improve our power to
detect linkage. Our results identified loci that appear to
influence TG levels in plasma and seem consistent with
a differential response to the presence of fenofibrate.
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